Browsing by Subject "Dolutegravir"
Now showing items 1-10 of 10
-
Adherence to antiretroviral therapy before and after substitution to Dolutegravir and associated factors among pregnant and postpartum mothers at the MUJHU supported facilities in Kampala - Uganda.
(Makerere University, 2023-01-19)Introduction: In 2020, the Uganda Ministry of health rolled out the use of dolutegravir based ART regimens as the preferred first line ART for all people living with HIV including the pregnant and postpartum mothers. Despite ... -
Association of weight gain with blood glucose trajectories in people living with HIV initiated on dolutegravir at Kisenyi health center IV, Kampala Uganda.
(Makerere University, 2024-09-30)Background: With the adoption of dolutegravir (DTG) in the first line antiretroviral therapy (ART) regimen as treatment of people living with HIV (PLWH), there has been observed weight gain and hyperglycemia among some ... -
Correlates of Virological non-suppression among children and adolescents aged 5-19 years on Dolutegravir based regimens attending Gulu Regional Referral Hospital, Northern Uganda : a mixed methods cross-sectional study
(Makerere University, 2024)Background: HIV/AIDS remains the leading cause of mortality and morbidity among children and adolescents living with HIV/AIDS and Sub-Saharan Africa bears the burden of virological non-suppression with children and adolescents ... -
Development and validation of an HPLC-UV method for the simultaneous determination of Efavirenz and Dolutegravir in human plasma
(Makerere University, 2022-12)Background: Although HIV/AIDS possess a challenge, global efforts have been mounted to address the epidemic. These include the massive role out of anti-retroviral therapy (ART) globally. To date either efavirenz or ... -
Model-based prediction of Dolutegravir dose requirement for HIV exposed neonates in Uganda
(Makerere University, 2024)Introduction: Mother-to-child transmission of HIV is the primary source of HIV infections in children, especially in low-income countries accounting for 14% of all new infections in Uganda. It is recommended that HIV-exposed ... -
Prevalence and factors associated with Dolutegravir-related hyperglycemia among children and adolescents <18 years attending Soroti Regional Referral and Lira Regional Referral Hospitals
(Makerere University, 2023-07)Background: The World Health Organization (WHO) recommended Dolutegravir (DTG) as the preferred anchor drug in first and second line Anti-Retroviral Treatment (ART) regimens owing to its high genetic barrier to resistance, ... -
Prevalence and Factors associated with Hyperglycaemia among Youth (15-24 years) on Dolutegravir attending selected HIV clinics in Kampala, Uganda
(Makerere University, 2024-10)Background: Noncommunicable diseases are increasingly causing higher mortality and morbidity among HIV patients due to extended lifespan, drug effects and unhealthy lifestyles. Dolutegravir is linked to adverse effects ... -
Prevalence and factors influencing suboptimal adherence to dolutegravir-based regimens among adult patients at Joint Clinical Research Center, Lubowa
(Makerere University, 2022-12)Background: An estimated 37.7 million people are living with HIV globally with the majority being in sub-Saharan Africa. There is a need to address suboptimal adherence to prevent dolutegravir resistance in order to maintain ... -
Prevalence of neuropsychiatric adverse events and associated factors among adult patients on Dolutegravir attending Mulago ISS clinic.
(Makerere University, 2022-02)Introduction: Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor that is recommended by World Health Organization for use as the preferred first line and second line anti-retroviral regimen ... -
Prevalence, associated factors and management of suspected adverse drug reactions among patients taking dolutegravir in Uganda
(Makerere University, 2024-04-30)In 2018, Uganda introduced a newer first-line Antiretroviral Therapy (ART) medicines approved by the World Health Organization (WHO)-Dolutegravir (DTG). The ambitious roll-out of these HIV treatment strategies was not ...